Abstract
Background:
We evaluated the cumulative incidence rate (CIR) of central nervous system (CNS) and non-CNS progression in alectinib-treated patients with anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer (NSCLC) to determine the extent to which alectinib may treat or control CNS disease.
Methods:
Patients with crizotinib-pretreated locally advanced or metastatic disease received alectinib 600 mg orally twice daily in two phase II trials. All patients underwent baseline imaging and regular centrally reviewed scans.
Results:
At 24 months, the CIR for CNS progression was lower in patients without vs with baseline CNS metastases (8.0 vs 43.9%). Patients with baseline CNS disease and prior radiotherapy had a higher CIR of CNS progression than radiotherapy-naive patients (50.5 vs 27.4%) and a lower CIR of non-CNS progression (25.8 vs 42.5%). Adverse events leading to withdrawal occurred in 5.9% and 6.7% of patients with and without baseline CNS metastases, respectively.
Conclusions:
This analysis indicates a potential role for alectinib in controlling and preventing CNS metastases.
| Original language | English |
|---|---|
| Pages (from-to) | 38-42 |
| Number of pages | 5 |
| Journal | British Journal of Cancer |
| Volume | 118 |
| Issue number | 1 |
| DOIs | |
| Publication status | Published - 16 Nov 2017 |
| Externally published | Yes |
Bibliographical note
Funding Information:SG has participated in advisory boards for Genentech/Roche, Ariad, Pfizer, and Bristol-Myers Squibb, and received honoraria for non-branded presentations for Genentech/Roche; ATS has participated in advisory boards for Pfizer, Novartis, Roche/Genentech, Ariad, Blueprint Medicines, Loxo, and EMD Serono, and received honoraria for non-branded presentations for Pfizer, Novartis, Genentech/Roche, Ignyta, Taiho and Foundation Medicine; FB has participated in advisory boards for Genentech/Roche, Novartis, and Pfizer, and received honoraria for non-branded presentations for Genentech/Roche and Novartis; LC has received honoraria from AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, and Pfizer; JC-HY has participated in compensated advisory boards for Boehringer Ingelheim, Eli Lilly, Bayer, Roche/Genen-tech/Chugai, Astellas, MSD, Merck Serono, Pfizer, Novartis, Clovis Oncology, Celgene, Merrimack, Yuhan Pharmaceuticals, Bristol-Myers Squibb, and Ono Pharmaceutical, and in an uncompensated advisory board for AstraZeneca; A-MCD has participated in advisory boards for Genentech/Roche, Pfizer, Eli Lilly, Clovis, and MSD, and received honoraria for non-branded presentations for Genentech/Roche and AstraZeneca (paid to her institute); D-WK has no conflict of interest to disclose; FdM has participated in advisory boards for Genentech/Roche, Boehringer, and Novartis, and received honoraria for non-branded presentations from Genentech/Roche, AstraZeneca, Bristol-Mayer Squibb, and Pfizer; MS is an employee of Genentech and owns Roche stocks; SL and RG are employees of Genentech and own shares in the company; AK is an employee of F. Hoffmann-La Roche Ltd and owns shares in the company; S-HIO has acted in a consulting or advisory role to ARIAD, AstraZeneca, Boehringer Ingelheim, Novartis, and Roche, and participated in Speaker Bureaus for AstraZeneca, Boehringer Ingelheim, and Roche/Genentech.
Funding Information:
We thank the patients, their families, and the participating centres for both studies. Third-party medical writing assistance, under the direction of the authors, was provided by Fiona Fernando of Gardiner-Caldwell Communications and funded by F. Hoffmann-La Roche Ltd.
